Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-08-30
2005-08-30
Scheiner, Laurie (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S199100, C424S204100, C424S093200, C435S069300, C435S236000, C435S320100, C435S456000
Reexamination Certificate
active
06936257
ABSTRACT:
A prophylactic or therapeutic vaccine for use in protecting mammals such as humans or animals against Venezelan Equine Encephalitis virus (VEE) is described. In particular, the vaccine comprises a recombinant virus such as a recombinant vaccinia virus which is able to express the structural genes of VEE in attenuated form, which has been modified to increase the protective effect of the vaccine. This is achieved by modifying the sequence of the attenuated VEE strain and/or putting this under the control of modified promoter which increases expression from the vector. Formulations of the vaccine as well as methods of treatment using the vaccine are also described.
REFERENCES:
patent: 5185440 (1993-02-01), Davis et al.
patent: 5505947 (1996-04-01), Johnston et al.
patent: WO 98/53077 (1998-11-01), None
Grieder et al, “Specific Restrictions in the progression of Venezuelan Equine . . . ” Virology 206, 1995, pp. 994-1006.
Kinney R M et al.: “Recombinant vaccinia/Venezuelan equine encephalitis (VEE) virus expresses VEE structural proteins.” Journal of General Virology, (Dec. 1988) 69 (PT 12) 3005-13., pp. 3005-3006, 3007.
Davison, Andrew J. et al.: “Structure of vaccinia virus early promoters” J. Mol. Biol. (1989), 210 (4), 749-69.
Kinney R M et al.: “The full-length nucleotide sequences of the virulent Trinidad donkey strain of venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83.” VIROLOGY, (May 1989) 170 (1) 19-30.
Hunt A R et al.: “Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses.” VACCINE, (Feb. 1995) 13 (3) 281-8.
Agapov E V et al.: “Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection.” Archives of Virology, (1994) 139 (1-2) 173-81.
Bennett A M et al.: “Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus.” Viral Immunology, (1998) 11 (3) 109-17.
Scheiner Laurie
The Secretary of State for Defence
LandOfFree
Recombinant Venezuelan equine encephalitis virus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant Venezuelan equine encephalitis virus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant Venezuelan equine encephalitis virus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468672